Earnings per share for the last twelve months: Zentalis Pharma (ZNTL)

ZNTL (Zentalis Pharmaceuticals, Inc.) - company brandmark

Zentalis Pharmaceuticals (ZNTL) relies on a stable staff of leading oncologists and chemists. Net income per share over the last 12 months demonstrates local dynamics, with the value holding at -1.92. The business is based on non-cyclical demand in breast cancer therapy, utilizing external CRO and CMO capacities to minimize operational risks during the development of new molecules.

ZNTL (Zentalis Pharma) Net earnings per share for the last 12 months history from 07/04/2022 to 11/18/2026

Analytical breakdowns for Zentalis Pharmaceuticals (ZNTL)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analysis:Zentalis Pharma (ZNTL)
Mass-produced product of Zentalis Pharma

Net income per share (TTM) serves as a fundamental filter to separate the underlying trend from market noise. This metric normalizes the company's total income by the number of securities, allowing for a comparison of business efficiency against industry benchmarks. The current trailing twelve-month earnings per share value is -1.92. This figure reflects the financial stability of Zentalis Pharmaceuticals (ZNTL). The brand's high scientific authority in oncology therapy determines the long-term dynamics of this profitability.